A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

Exclusion Criteria

• •1. Subjects with other histopathological types of cervical cancer, such as small cell carcinoma, sarcoma, etc.
• •2. FIGO 2018 IVB
• •3. Subjects who had previously undergone total hysterectomy
• •4. Subjects who cannot receive brachytherapy
• •5. Subjects with other active malignancies within 2 years prior to randomization
• •6. Clinically significant hydronephrosis that cannot be relieved by nephrostomy or ureteral stenting as judged by the Investigator
• •7. Any prior treatments targeting the mechanism of tumor immunity, such as immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PDL1 antibody, anti-CTLA-4 antibody, etc.), or therapy against immune costimulatory factors (e.g., antibodies directed against ICOS, CD40,CD137, GITR, OX40 targets, etc).
• •8. Subjects who require systemic treatment with glucocorticoid (\>10 mg/day of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior to randomization;
• •9. Major surgical treatment, open biopsy or significant trauma within 4 weeks prior to randomization; or elective major surgical treatment required during the study
• •10. Use of live vaccines within 4 weeks prior to randomization
• •11. Active or potentially recurrent autoimmune disease
• •12. Known primary or secondary immunodeficiencies, including testing positive for human immunodeficiency virus (HIV) antibodies
• •13. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
• •14. Known history of interstitial lung disease or non-infectious pneumonitis
• •15. Pregnant or lactating women.
• •16. Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug.